secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001104659-23-088370
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics updates corporate presentation; cash $102M, pipeline catalysts outlined
--------------------------------------------------------------------------------

- Cash position $102M as of June 30, 2023, no debt, cash runway at least 12 months.
- KORSUVA injection launched in US (Apr 2022) and EU (Sep 2022); Japan approval expected 2H23.
- Oral difelikefalin in phase 3 for advanced CKD (KICK1/2, topline 2H24) and atopic dermatitis (KIND1/2, topline 1H25).
- Phase 2/3 for notalgia paresthetica (KOURAGE1) initiated 1Q23, topline 2H26.
- Partner CSL Vifor handles commercialization; Cara has no cash outlay for commercial costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923088370/0001104659-23-088370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923088370/tm2322717d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer